Contineum Therapeutics Debt
| CTNM Stock | 14.30 0.14 0.97% |
At this time, Contineum Therapeutics' Short Term Debt is very stable compared to the past year. As of the 16th of February 2026, Debt To Equity is likely to grow to 0.04, though Net Debt is likely to grow to (17.1 M). Contineum Therapeutics' financial risk is the risk to Contineum Therapeutics stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.0265 | Current Value 0.0251 | Quarterly Volatility 0.34437047 |
Contineum | Build AI portfolio with Contineum Stock |
Contineum Therapeutics Bond Ratings
Contineum Therapeutics Class financial ratings play a critical role in determining how much Contineum Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Contineum Therapeutics' borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | (6.22) | Unlikely Manipulator | View |
Contineum Therapeutics Total Assets Over Time
Contineum Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Contineum Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Contineum Therapeutics Debt Ratio | 2.51 |
Contineum Therapeutics Corporate Bonds Issued
Contineum Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Contineum Therapeutics Use of Financial Leverage
Leverage ratios show Contineum Therapeutics' total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of Contineum Therapeutics' financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 7.2 M | 6.8 M | |
| Net Debt | -18 M | -17.1 M | |
| Long Term Debt | 3.3 M | 2.9 M | |
| Short and Long Term Debt | 4.5 M | 2.9 M | |
| Short Term Debt | 1.3 M | 1.6 M | |
| Net Debt To EBITDA | 0.34 | 0.32 | |
| Debt To Equity | 0.04 | 0.04 | |
| Interest Debt Per Share | 0.29 | 0.28 | |
| Debt To Assets | 0.03 | 0.03 | |
| Long Term Debt To Capitalization | 1.39 | 1.46 | |
| Total Debt To Capitalization | 0.03 | 0.03 | |
| Debt Equity Ratio | 0.04 | 0.04 | |
| Debt Ratio | 0.03 | 0.03 | |
| Cash Flow To Debt Ratio | (4.72) | (4.96) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Contineum Therapeutics Financial Statements. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Will Pharmaceuticals sector continue expanding? Could Contineum diversify its offerings? Factors like these will boost the valuation of Contineum Therapeutics. Projected growth potential of Contineum fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Contineum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Contineum Therapeutics requires distinguishing between market price and book value, where the latter reflects Contineum's accounting equity. The concept of intrinsic value - what Contineum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Contineum Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Contineum Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Contineum Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Contineum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.